Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARG-01 Argipressin in Liver Resection
2024-514332-25-00Phase 2Completed
- Sponsor
- Region Västra Götaland
- Start
- Nov 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatic neoplasm, hepatocellular carcinoma (HCC), hepatic metastasis and 1 more comparing Argipressin (Empressin) with Placebo (saline) (2 arms). Primary endpoint: Intraoperative blood loss. Started Nov 2024; status: completed.
02
Drugs
vasopressin
03
Conditions
hepatic neoplasmhepatocellular carcinoma (HCC)hepatic metastasisBenign hepatic neoplasm (BHN)
Beyond the preview
Go deeper on 2024-514332-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514332-25-00.